vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and MOBIX LABS, INC (MOBX). Click either name above to swap in a different company.
Bolt Biotherapeutics, Inc. is the larger business by last-quarter revenue ($2.5M vs $1.9M, roughly 1.3× MOBIX LABS, INC). Bolt Biotherapeutics, Inc. runs the higher net margin — -265.2% vs -540.0%, a 274.8% gap on every dollar of revenue. Over the past eight quarters, MOBIX LABS, INC's revenue compounded faster (28.0% CAGR vs -31.2%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
BOLT vs MOBX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $1.9M |
| Net Profit | $-6.6M | $-10.1M |
| Gross Margin | — | 31.0% |
| Operating Margin | -283.4% | -471.1% |
| Net Margin | -265.2% | -540.0% |
| Revenue YoY | — | -40.8% |
| Net Profit YoY | 58.4% | 49.0% |
| EPS (diluted) | $-9.38 | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $1.9M | ||
| Q3 25 | $2.2M | $1.9M | ||
| Q2 25 | $1.8M | $2.4M | ||
| Q1 25 | $1.2M | $2.5M | ||
| Q4 24 | $0 | $3.2M | ||
| Q3 24 | $1.1M | $3.0M | ||
| Q2 24 | $1.3M | $2.1M | ||
| Q1 24 | $5.3M | $1.1M |
| Q4 25 | $-6.6M | $-10.1M | ||
| Q3 25 | $-7.1M | $-15.7M | ||
| Q2 25 | $-8.6M | $-8.3M | ||
| Q1 25 | $-11.0M | $-2.3M | ||
| Q4 24 | $-15.9M | $-19.8M | ||
| Q3 24 | $-15.2M | $-11.5M | ||
| Q2 24 | $-21.2M | $-7.7M | ||
| Q1 24 | $-10.8M | $-1.8M |
| Q4 25 | — | 31.0% | ||
| Q3 25 | — | 50.5% | ||
| Q2 25 | — | 57.4% | ||
| Q1 25 | — | 40.6% | ||
| Q4 24 | — | 53.2% | ||
| Q3 24 | — | 56.6% | ||
| Q2 24 | — | 35.5% | ||
| Q1 24 | — | 16.9% |
| Q4 25 | -283.4% | -471.1% | ||
| Q3 25 | -355.1% | -834.9% | ||
| Q2 25 | -510.5% | -343.4% | ||
| Q1 25 | -991.4% | -311.7% | ||
| Q4 24 | — | -461.7% | ||
| Q3 24 | -1441.1% | -378.0% | ||
| Q2 24 | -1772.3% | -454.2% | ||
| Q1 24 | -324.1% | -747.8% |
| Q4 25 | -265.2% | -540.0% | ||
| Q3 25 | -329.4% | -835.8% | ||
| Q2 25 | -474.6% | -352.0% | ||
| Q1 25 | -903.4% | -91.2% | ||
| Q4 24 | — | -626.0% | ||
| Q3 24 | -1330.1% | -390.6% | ||
| Q2 24 | -1662.4% | -373.1% | ||
| Q1 24 | -205.0% | -153.1% |
| Q4 25 | $-9.38 | $-0.16 | ||
| Q3 25 | $-3.72 | $-0.26 | ||
| Q2 25 | $-4.46 | $-0.17 | ||
| Q1 25 | $-0.29 | $-0.06 | ||
| Q4 24 | $-13.73 | $-0.52 | ||
| Q3 24 | $-7.93 | $-0.33 | ||
| Q2 24 | $-11.12 | $-0.25 | ||
| Q1 24 | $-0.28 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | — |
| Total DebtLower is stronger | — | $6.3M |
| Stockholders' EquityBook value | $26.5M | $4.7M |
| Total Assets | $56.7M | $32.7M |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | — | ||
| Q3 25 | $31.9M | — | ||
| Q2 25 | $34.8M | — | ||
| Q1 25 | $38.8M | — | ||
| Q4 24 | $47.3M | — | ||
| Q3 24 | $53.8M | — | ||
| Q2 24 | $73.7M | — | ||
| Q1 24 | $91.3M | — |
| Q4 25 | — | $6.3M | ||
| Q3 25 | — | $6.2M | ||
| Q2 25 | — | $4.4M | ||
| Q1 25 | — | $4.6M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | — | $3.2M | ||
| Q1 24 | — | $3.2M |
| Q4 25 | $26.5M | $4.7M | ||
| Q3 25 | $32.1M | $-336.0K | ||
| Q2 25 | $38.8M | $425.0K | ||
| Q1 25 | $46.8M | $342.0K | ||
| Q4 24 | $57.2M | $-3.0M | ||
| Q3 24 | $72.0M | $5.5M | ||
| Q2 24 | $85.9M | $8.5M | ||
| Q1 24 | $104.2M | $4.2M |
| Q4 25 | $56.7M | $32.7M | ||
| Q3 25 | $65.1M | $37.1M | ||
| Q2 25 | $75.5M | $34.6M | ||
| Q1 25 | $85.9M | $36.5M | ||
| Q4 24 | $99.6M | $37.3M | ||
| Q3 24 | $109.3M | $39.1M | ||
| Q2 24 | $124.2M | $41.3M | ||
| Q1 24 | $142.9M | $29.5M |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 10.26× | ||
| Q1 25 | — | 13.44× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.62× | ||
| Q2 24 | — | 0.38× | ||
| Q1 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-4.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-4.8M | ||
| Q3 25 | $-9.7M | $-4.5M | ||
| Q2 25 | $-9.6M | $-4.1M | ||
| Q1 25 | $-13.4M | $-586.0K | ||
| Q4 24 | $-14.4M | $-930.0K | ||
| Q3 24 | $-14.0M | $-3.6M | ||
| Q2 24 | $-16.1M | $-3.1M | ||
| Q1 24 | $-16.8M | $-8.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-14.0M | $-4.6M | ||
| Q2 24 | — | $-3.1M | ||
| Q1 24 | — | $-9.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1227.6% | -157.1% | ||
| Q2 24 | — | -151.8% | ||
| Q1 24 | — | -794.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.6% | 34.5% | ||
| Q2 24 | 0.0% | 2.2% | ||
| Q1 24 | 0.0% | 87.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BOLT
Segment breakdown not available.
MOBX
| US | $1.7M | 92% |
| Other | $155.0K | 8% |
